Abstract:In the absence of an effective vaccine to prevent HCMV infections, alternative interventions must be developed. Prevention of viral entry into susceptible cells is an attractive alternative strategy. Here we report that heparan sulfate-binding peptides effectively inhibit entry into fibroblasts of in vitro-derived CMVs and partially inhibit in vivo-derived CMVs. This includes the inhibition of urine-derived HCMV (uCMV), which is highly resistant to antibody neutralization. While these antiviral peptides are highly effective at inhibiting cell-free virus, they do not inhibit MCMV cell-to-cell spread. This underscores the need to understand the mechanism of cell-to-cell spread and differences between in vivo-derived versus in vitro-derived CMV entry to effectively prevent CMV’s spread. ABSTRACT Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that can cause severe disease following in utero exposure, during primary infection, or latent virus reactivation in immunocompromised populations. These complications lead to a 1- to 2-billion-dollar economic burden, making vaccine development and/or alternative treatments a high priority. Current treatments for HCMV include nucleoside analogues such as ganciclovir (GCV), foscarnet, and cidofovir. Recently, letermovir, a terminase complex inhibitor, was approved for prophylaxis after stem cell transplantation. These treatments have unwanted side effects, and HCMV is becoming resistant to them. Therefore, we sought to develop an alternative treatment that targets a different stage in viral infection. Currently, small antiviral peptides are being investigated as anti-influenza and anti-HIV treatments. We have developed heparan sulfate-binding peptides as tools for preventing CMV infections. These peptides are highly effective at stopping infection of fibroblasts with in vitro-derived HCMV and murine cytomegalovirus (MCMV). However, they do not prevent MCMV infection in vivo. Interestingly, these peptides inhibit infectivity of in vivo-derived CMVs, albeit not as well as tissue culture-grown CMVs. We further demonstrate that this class of heparan sulfate-binding peptides is incapable of inhibiting MCMV cell-to-cell spread, which is independent of heparan sulfate usage. These data indicate that inhibition of CMV infection can be achieved using synthetic polybasic peptides, but cell-to-cell spread and in vivo-grown CMVs require further investigation to design appropriate anti-CMV peptides. IMPORTANCE In the absence of an effective vaccine to prevent HCMV infections, alternative interventions must be developed. Prevention of viral entry into susceptible cells is an attractive alternative strategy. Here we report that heparan sulfate-binding peptides effectively inhibit entry into fibroblasts of in vitro-derived CMVs and partially inhibit in vivo-derived CMVs. This includes the inhibition of urine-derived HCMV (uCMV), which is highly resistant to antibody neutralization. While these antiviral peptides are highly effective at inhibiting cell-free virus, they do not inhibit MCMV cell-to-cell spread. This underscores the need to understand the mechanism of cell-to-cell spread and differences between in vivo-derived versus in vitro-derived CMV entry to effectively prevent CMV’s spread.

Production- and Purification-Relevant Properties of Human and Murine Cytomegalovirus

Cytokine responses to major human Cytomegalovirus antigens in mouse model

A Novel Polyclonal Antibody Against Human Cytomegalovirus: General Characteristics and Potential Application in Diagnosis

Construction and Characterization of a High-Capacity Replication-Competent Murine Cytomegalovirus Vector for Gene Delivery

Spatial kinetics and immune control of murine cytomegalovirus infection in the salivary glands

Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus

Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH

A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral Gh/gl/pul128-131 Pentameric Complex

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of In Vitro Screenings

Development of Two Potential Diagnostic Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein B

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.

Functional Analysis of Human Cytomegalovirus UL/b' Region Using SCID-hu Mouse Model.

Expression and Purification of Human Cytomegalovirus Tegument Protein Pp65 and Analysis of Its Immunologic Characteristics

Immune surveillance of cytomegalovirus in tissues

Virological, innate, and adaptive immune profiles shaped by variation in route and age of host in murine cytomegalovirus infection

Development of a mouse salivary gland-derived mesenchymal cell line for immunological studies of murine cytomegalovirus.

Antibody-Independent Quantification of Cytomegalovirus Virion Protein Incorporation Using HiBiT

Comprehensive Analysis of Soluble Mediator Profiles in Congenital CMV Infection Using an MCMV Model